drugset / Trial / NCT07548697
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Phase 0
Recruiting
24 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CARsgen Life Sciences Co.,Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, open label, dose exploring clinical study to evaluate the safety, efficacy, metabolic kinetics and pharmacodynamics of CT1182 cells in patients with relapsed / refractory B-cell non Hodgkin lymphoma (r/r B-NHL).
Timeline
- Start
- 2026-04-30
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT1182 | Cell therapy | 1.2e+08 cells | Intravenous |
| Subject | CT1182 | Cell therapy | 3e+08 cells | Intravenous |
| Subject | CT1182 | Cell therapy | 6e+08 cells | Intravenous |